| ¿µ¹® | malignant tumor | ÇÑ±Û | ¾Ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-ÈÇÐÀû-»ý¹°ÇÐÀûÀÎ ¹ß¾Ï ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² ÈÇй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù. |
||
| ¿µ¹® | malignant melanoma | ÇÑ±Û | ¾Ç¼ºÈæ»öÁ¾ |
|---|---|---|---|
| ¼³¸í | ÇǺο¡¼ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁÖ·Î ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇÏ´Â µå¹® º´À¸·Î ÇÇºÎ¿Í ±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼ À¯·¡ÇÏ´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀÎ °ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | multiple sclerosis | ÇÑ±Û | ´Ù¹ß°æÈÁõ |
|---|---|---|---|
| ¼³¸í | ½Å°æÃà»èÀ» µÑ·¯½Î°í ÀÖ´Â ¸»ÀÌÁý(myelin sheath)ÀÇ ÆÄ±«·Î ÀÎÇÑ º´Àû»óŸ¦ ¸»ÇÔ. ÆÄ±«µÈ ¸»ÀÌÁýÀº ÈäÅ͸¦ ³²±â°Ô µÇ¾î ½Å°æÃà»èÀ» ÅëÇÑ ½Å°æÀü´ÞÀÌ Á¦´ë·Î µÇÁö ¾Ê¾Æ ¿îµ¿, °¨°¢, ÀÚÀ²½Å°æ ¸ðµÎÀÇ ½Å°æÀü´ÞÀå¾Ö°¡ ³ªÅ¸³´Ù. ÀÌ º´ÅÍ´Â ¾îµð¼³ª ³ªÅ¸³¯ ¼ö ÀÖ¾î¼ ±× Àå¾Ö°¡ ³ªÅ¸³ª´Â ºÎÀ§¿¡ µû¶ó ¼·Î ´Ù¸¥ Áõ»óÀ» È£¼ÒÇÑ´Ù. |
||
| ¿µ¹® | multiple myeloma | ÇÑ±Û | ´Ù¹ß°ñ¼öÁ¾ |
|---|---|---|---|
| ¼³¸í | ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼ À¯·¡ÇÑ °ÍÀÌ¾î¼ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇÏ´Â ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈÇÑ ´Ù¹ß °ñ¼öÁ¾ ȯÀÚ¿¡¼µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀÎ °æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ ȯÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ°¡ ÀϾÙ. °ñ¼öÁ¾ ȯÀÚ¿¡¼´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù. |
||
| ¿µ¹® | multiple personality | ÇÑ±Û | ´ÙÀμº ÀÎ°Ý |
|---|---|---|---|
| ¼³¸í | ÇØ¸®¼º Á¤½ÅÀå¾ÖÀÇ Çϳª·Î ³ªÅ¸³´Ù. ÇÑ »ç¶÷ÀÌ ¿©·¯ »ç¶÷ÀÇ ¼º°ÝÀ» ¼ÒÀ¯Çϰí ÀÖ´Â °ÍÀ¸·Î ¸¶Ä¡ ¡°Áöų¹Ú»ç¿Í ÇÏÀÌµå ¾¾¡±¿Í °°Àº °æ¿ìÀÌ´Ù. ¾Æ¸¶, ÇöÀç ÀÚ½ÅÀÇ Ã³Áö¿¡¼ ¹þ¾î³ª°í ½ÍÀº ¹«ÀǽÄÀûÀÎ ¿å¸Á¿¡¼ ºñ·ÔµÇ´Â °ÍÀ¸·Î ¿©°ÜÁø´Ù. |
||
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
|---|---|
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
| MH | malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam... |
| MHS | major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m... |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| R.E.A.L. | Revised European American Classification of Lymphoid Neoplasms |
|---|---|
| HIV AN | HIV associated nephropathy |
| HIV- | HIV negative |
| HIV+ | HIV positive |
| HIV Pr | HIV protease |
| neoplasms, multiple primary | Two or more abnormal growths of tissue occurring simultaneously. The neoplasms are histologically different and may be found in the same or different sites. (12 Dec 1998) |
|---|---|
| middle stage HIV disease | <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| anti-HIV agents | Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids. (12 Dec 1998) |
| receptors, HIV | Cellular receptors that bind the human immunodeficiency virus that causes aids. Included are CD4 antigens, found on t4 lymphocytes, and monocytes/macrophages, which bind to the HIV envelope protein gp120. (12 Dec 1998) |
| chronic symptomatic HIV infection | This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| primary HIV infection | <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands. (06 Mar 1998) |
| HIV | <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified. Type 1: the retrovirus recognised as the agent that induces AIDS. Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa. Acronym: HIV (11 Nov 1997) |
| HIV-1 | The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte. (12 Dec 1998) |
| HIV-1 reverse transcriptase | <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV-2 | An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian lentivirus siv and infects only t4-lymphocytes expressing the CD4 phenotypic marker. (12 Dec 1998) |
| HIV-2 protease | <enzyme> Processes hiv-1pr53(gag) and analogous junction peptides in vitro; less than 60% amino acid identity to hiv-1 protease Registry number: EC 3.4.23.- Synonym: hiv2 protease (26 Jun 1999) |
| HIV-2 reverse transcriptase | <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91) Registry number: EC 2.7.7.- (26 Jun 1999) |
| HIV antibodies | Antibodies reactive with human immunodeficiency virus (HIV, previously called HTLV-III/lav) antigens of aids. This includes HIV-1 antibodies and HIV-2 antibodies. (12 Dec 1998) |
| HIV antigens | Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens. (12 Dec 1998) |
| HIV core protein p24 | A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|